Comparative AAPOS Validation of the Birefringent Amblyopia Screener with Isolated Small-Angle Strabismus
Authors Arnold RW
Received 13 December 2019
Accepted for publication 16 January 2020
Published 31 January 2020 Volume 2020:14 Pages 325—329
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Robert W Arnold
Alaska Blind Child Discovery, Alaska Children’s Eye and Strabismus, Anchorage, AK, USA
Correspondence: Robert W Arnold
Alaska Blind Child Discovery, Alaska Children’s Eye and Strabismus, 3500 Latouche #280, Anchorage, AK 99508, USA
Tel +1 907 561-1917
Fax +1 907 563-5373
Background: The Rebion blinq binocular birefringent ocular alignment screener was recently commercially released, but it did not yet have validation by American Association for Pediatric Ophthalmology and Strabismus (AAPOS) uniform guidelines.
Methods: Children and adults from a high-risk eye practice had screening by blinq with validation by AAPOS 2003 guidelines. Then, the blinq was compared to the Adaptica 2WIN with CR corneal reflex strabismus estimation by AAPOS 2003 guidelines plus additional efforts to identify patients with diminished binocularity.
Results: Blinq in 100 patients compared to 2003 AAPOS amblyopia risk factors (ARF) had sensitivity 67%, specificity 75% and PPV of 82%. Both blinq and 2WIN were completed by 87 patients median age 6.5 years. Sensitivity, specificity and positive predictive value (PPV) for blinq were 75%, 68% and 81% whereas 2WIN had 91%, 68% and 84%. The blinq referred two young patients with isolated, small-angle strabismic amblyopia that 2WIN refractive function passed.
Conclusion: Despite its non-refractive design to identify binocular foveation, blinq performed well with refractive and strabismic uniform risk factors and a PPV greater than 80%.
Clinical Trials Registry: NCT04195711.
Keywords: birefringent, photoscreening, amblyopia, fixation instability, amblyopia risk factor, strabismus
A Letter to the Editor has been published for this article.
A Response to Letter has been published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]